Somatostatin Receptor Subtype 5 Regulation of Islet Neoplasia
Somatostatin Receptor Subtype 5 Regulation of Islet Neoplasia
批准号:
8627441
负责人:
FRANCIS CHARLES BRUNICARDI
金额:
$1.2万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2013-08-31
中文摘要
摘要:在当前R-01的资助期间,我们团队有4项与人类和人类有关的发现
小鼠生长抑素受体亚型5(hSSTR5、mSSTR5)和胰腺十二指肠同源盒-1(PDX-1)
对于患有胰岛肿瘤(Ineo)的患者来说是高度可翻译的:1.我们的SSTR5-/-小鼠患上了Ineo
与高胰岛素血症、低血糖和PDX-1过度表达有关,提示mSSTR5调节
胰岛素分泌和Ineo均通过PDX-1实现;2.PDX-1调节Ineo细胞增殖和静脉注射PDX-1 shRNA
治疗预防转移性胰岛素瘤小鼠模型中的低血糖死亡,提示PDX-1是一种
Ineo的分子靶点;3.我们发现了一个生殖系hSSTR5 SNP,在C位有一个由Pro取代为亮氨酸的SNP
末端位置335(HSSTR5 P335L)在约50%的人眼部肿瘤中存在。初步的体外数据显示,
HSSTR5 P335L功能低下导致PDX-1过度表达,对SSTR5类似物缺乏反应
在Ineo细胞中的PRL-1980,表明基因组hSSTR5变异预测治疗反应;4.我们的大鼠胰岛素
可以使用由PDX-1激活的启动子-胸苷激酶(RIP-TK)载体和F18-FHBG前药
目的:对PDX-1在小鼠Ineo肿瘤中的表达进行成像,并可用于追踪治疗反应。
假设:a)hSSTR5通过PDX-1调节胰岛素和Ineo,b)hSSTR5 P335L是一个功能低下的受体
C)hSSTR5的基因组变异和hSSTR5基因表达的变异
HSSTR5、hSSTR5 P335L和PDX-1预测靶向治疗的反应。具体目标1:确定
是否可以使用TaqMan等位基因验证hSSTR5基因组变异在Ineo患者中的分布
Ineo细胞hSSTR5、hSSTR5 P335L和/或PDX-1基因表达的差异
标本可以使用QPCR、Western印迹和量子点(Q Dot)去卷积成像进行验证,并
图像分析。特定目的2:确定a)hSSTR5是否调节胰岛素和Ineo细胞的增殖
通过PDX-1,b)hSSTR5 P335L是一种功能低下的受体,但PDX-1对Ineo的调节发生了变化,以及c)
HSSTR5基因组变异和hSSTR5、hSSTR5 P335L和PDX-1表达水平的变异可预测
SCID小鼠对SSTR5特异性类似物PRL-1980与PDX-1 shRNA治疗的反应
模型,二)β;TC-6hSSTR5 P335L SCID小鼠模型,三)β;TC-6SSTR5KD(敲击)SCID小鼠模型,四)hSSTR5
敲除小鼠,v)hSSTR5 P335L敲入小鼠和vi)SSTR5-/-小鼠。具体目标3:确定是否
A)使用大鼠胰岛素启动子-胸苷激酶(RIP-TK)在Ineo中检测PDX-1表达的显像剂
可以使用18F-FHBG对来自AIM 2的小鼠模型进行microPET成像和/或双标记
光学成像和断层扫描的类似物,b)对靶向治疗的反应可以使用
RIP-TK/18F-FHBG microPET成像,取决于PDX-1的表达水平和c)microPET PRL-
1980年-Cu64成像可以区分SSTR5阳性和SSTR5阴性的新生血管肿瘤和Will
确认PDX-1在体内治疗反应中的作用。
英文摘要
ABSTRACT: During the funding of the current R-01, our team made 4 discoveries related to human and
mouse somatostatin receptor subtype five (hSSTR5, mSSTR5) and pancreatic duodenal homeobox-1 (PDX-1)
that are highly translatable for patients suffering with islet neoplasia (INeo): 1. our SSTR5-/- mice develop INeo
associated with hyperinsulinemia, hypoglycemia and PDX-1 overexpression, suggesting mSSTR5 regulates
both insulin secretion and INeo via PDX-1; 2. PDX-1 regulates INeo cell proliferation and iv PDX-1 shRNA
therapy prevents hypoglycemic death in a metastatic insulinoma mouse model, suggesting PDX-1 is a
molecular target for INeo; 3. we found a germline hSSTR5 SNP with a proline to leucine substitution at C
terminal position 335 (hSSTR5 P335L) in ~50% of human INeo tumors. Preliminary in vitro data reveal that
hSSTR5 P335L is hypofunctional resulting in PDX-1 overexpression and lack of response to SSTR5 analogue
PRL-1980 in INeo cells, suggesting genomic hSSTR5 variation predicts response to therapy; 4. our rat insulin
promoter-thymidine kinase (RIP-TK) vector, which is activated by PDX-1, and F18-FHBG prodrug can be used
to image PDX-1 expression in INeo tumors in mice and could be used to track response to therapy.
Hypotheses: a) hSSTR5 regulates insulin and INeo via PDX-1, b) hSSTR5 P335L is a hypofunctional receptor
with altered PDX-1 regulation of INeo, and c) genomic variation of hSSTR5 and variations in expression of
hSSTR5, hSSTR5 P335L and PDX-1 predict response to targeted therapies. Specific Aim 1: to determine
whether a) distribution of hSSTR5 genomic variation in INeo patients can be validated using TaqMan Allelic
Discrimination assay and b) variations in expression of hSSTR5, hSSTR5 P335L and/or PDX-1 of INeo
specimens can be validated using QPCR, Western blot and Quantum Dot (Q Dot) deconvolution imaging and
image analysis. Specific aim 2: to determine whether a) hSSTR5 regulates insulin and INeo cell proliferation
via PDX-1, b) hSSTR5 P335L is a hypofunctional receptor with altered PDX-1 regulation of INeo, and c)
hSSTR5 genomic variation and variations in hSSTR5, hSSTR5 P335L and PDX-1 expression levels predict
response to SSTR5-specific analogue PRL-1980 vs PDX-1 shRNA therapies in i) βTC-6hSSTR5 SCID mouse
model, ii) βTC-6hSSTR5 P335L SCID mouse model, iii) βTC-6SSTR5KD (Knock Down) SCID mouse model, iv) hSSTR5
knock-in mice, v) hSSTR5 P335L knock-in mice and vi) SSTR5-/- mice. Specific Aim 3: to determine whether
a) imaging agents to detect PDX-1 expression using rat insulin promoter-thymidine kinase (RIP-TK) in INeo
mouse models from aim 2 can be validated using 18F-FHBG for microPET imaging and/or dual labeled
analogues for optical imaging and tomography, b) the response to targeted therapies can be studied using
RIP-TK/ 18F-FHBG microPET imaging and is dependent upon PDX-1 expression levels and c) microPET PRL-
1980-Cu64 imaging can differentiate between SSTR5 positive and SSTR5 negative INeo tumors and will
confirm the role of PDX-1 in therapeutic response in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Somatostatin Receptor Subtype 5 Regulation of Islet Neoplasia
-
批准号:8038523
-
项目类别:
-
资助金额:$20.86万
-
财政年份:2010
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Molecular Surgeon Symposium on Pancreatic Cancer
-
批准号:6670370
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2003
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
PDX-1 is a Therapeutic Target for Pancreatic Cancer
-
批准号:7526489
-
项目类别:
-
资助金额:$27.48万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Pancreatic Cancer Treatment Using Surgery & Gene Therapy
-
批准号:6874950
-
项目类别:
-
资助金额:$26.79万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
PDX-1 is a Therapeutic Target for Pancreatic Cancer
-
批准号:8269565
-
项目类别:
-
资助金额:$21.88万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Pancreatic Cancer Treatment Using Surgery & Gene Therapy
-
批准号:7052122
-
项目类别:
-
资助金额:$26.16万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Pancreatic Cancer Treatment Using Surgery & Gene Therapy
-
批准号:6623368
-
项目类别:
-
资助金额:$26.79万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
PDX-1 is a Therapeutic Target for Pancreatic Cancer
-
批准号:7662493
-
项目类别:
-
资助金额:$27.48万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
PDX-1 is a Therapeutic Target for Pancreatic Cancer
-
批准号:7841939
-
项目类别:
-
资助金额:$27.48万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
PDX-1 is a Therapeutic Target for Pancreatic Cancer
-
批准号:8082596
-
项目类别:
-
资助金额:$26.66万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Pancreatic Cancer Treatment Using Surgery & Gene Therapy
-
批准号:6465194
-
项目类别:
-
资助金额:$26.79万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Pancreatic Cancer Treatment Using Surgery & Gene Therapy
-
批准号:6745615
-
项目类别:
-
资助金额:$26.79万
-
财政年份:2002
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
INTRA CELL COMMUNICATION IN SURGICALLY ALTERED PANCREAS
-
批准号:6606408
-
项目类别:
-
资助金额:$7.53万
-
财政年份:1993
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Intraislet Communication in Surgically-Altered Pancreas
-
批准号:7009584
-
项目类别:
-
资助金额:$33.07万
-
财政年份:1993
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
INTRA-ISLET COMMUNICATION IN SURGICALLY ALTERED PANCREAS
-
批准号:2016660
-
项目类别:
-
资助金额:$9.79万
-
财政年份:1993
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Intraislet Communication in Surgically-Altered Pancreas
-
批准号:6723422
-
项目类别:
-
资助金额:$33.86万
-
财政年份:1993
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
INTRA-ISLET COMMUNICATION IN SURGICALLY ALTERED PANCREAS
-
批准号:2016659
-
项目类别:
-
资助金额:$8.18万
-
财政年份:1993
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
INTRA CELL COMMUNICATION IN SURGICALLY ALTERED PANCREAS
-
批准号:2905544
-
项目类别:
-
资助金额:$24.76万
-
财政年份:1993
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
Intraislet Communication in Surgically-Altered Pancreas
-
批准号:6850643
-
项目类别:
-
资助金额:$33.86万
-
财政年份:1993
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
INTRA-ISLET COMMUNICATION IN SURGICALLY ALTERED PANCREAS
-
批准号:2145665
-
项目类别:
-
资助金额:$8.27万
-
财政年份:1993
-
负责人:FRANCIS CHARLES BRUNICARDI
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Succinate-Succinate Receptor介导的代谢反应在正畸牙根吸收中的作用
-
批准号:82371007
-
项目类别:面上项目
-
资助金额:48万元
-
批准年份:2023
-
负责人:雷浪
-
依托单位:
Leptin receptor阳性细胞通过分泌Hedgehog蛋白调控椎间盘退变及修复的谱系研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:傅强
-
依托单位:
丹参酮ⅡA通过靶向TRAIL-receptor和ULBPs增强NK细胞抗非小细胞肺癌效应的作用及分子机制研究
-
批准号:81903932
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2019
-
负责人:龚陈媛
-
依托单位:
白介素-1受体相关激酶(Interleukin-1 receptor associated kinase,IRAK)-M调节哮喘气道炎症异质性和气道重塑以及相关机制的研究
-
批准号:81970025
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:高金明
-
依托单位:
无脊椎动物新型受体Parathyroid hormone receptor like (PTHRL) 的鉴定及其对赤拟谷盗表皮发育的调控
-
批准号:31872970
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:李斌
-
依托单位:
衰老过程中Lamin-B Receptor蛋白聚积通过扰乱干细胞竞争促进生殖干细胞丢失的分子机制研究
-
批准号:31671254
-
项目类别:面上项目
-
资助金额:65.0万元
-
批准年份:2016
-
负责人:陈海洋
-
依托单位:
Leptin Receptor负向调控应力刺激诱导的后纵韧带骨化的分子机制及转化研究
-
批准号:81401821
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:陈剑
-
依托单位:
受体相互作用蛋白3(Receptor-interacting protein 3,RIP3)调控神经元缺血性程序性坏死的作用及机制研究
-
批准号:81271272
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2012
-
负责人:罗本燕
-
依托单位:
抑素蛋白(prohibitin)1调控蛋白酶激活受体(protease-activated receptor)1内化转运及降解的功能和机制
-
批准号:31270835
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2012
-
负责人:张云
-
依托单位:
Retinoid X Receptor(RXR)α启动子甲基化在结直肠癌发生发展中的作用
-
批准号:81201582
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:张芬芬
-
依托单位: